One Year Assessment of the Hearing Preservation Potential of the EVO Electrode Array.

EVO electrode array HEARRING classification cochlear implantation functional hearing hearing preservation

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
29 Nov 2021
Historique:
received: 12 10 2021
revised: 15 11 2021
accepted: 25 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

A prospective longitudinal multicentre study was conducted to assess the one-year postsurgical hearing preservation profile of the EVO Fifteen adults presenting indications of electro-acoustic stimulation (pure-tone audiometry (PTA) thresholds ≤70 dB below 750 Hz) were implanted with the EVO™ electrode array. Hearing thresholds were collected at five time-points from CI activation to twelve months (12M) after activation. Hearing thresholds and hearing preservation profiles (HEARRING group classification) were assessed. All subjects had measurable hearing thresholds at follow-up. No case of complete loss of hearing or minimal hearing preservation was reported at any time point. At activation (N This study provides the first longitudinal follow-up on associated hearing profiles to the EVO™ electrode array, which are comparable to the literature. However, other studies on larger populations should be performed.

Sections du résumé

BACKGROUND BACKGROUND
A prospective longitudinal multicentre study was conducted to assess the one-year postsurgical hearing preservation profile of the EVO
METHODS METHODS
Fifteen adults presenting indications of electro-acoustic stimulation (pure-tone audiometry (PTA) thresholds ≤70 dB below 750 Hz) were implanted with the EVO™ electrode array. Hearing thresholds were collected at five time-points from CI activation to twelve months (12M) after activation. Hearing thresholds and hearing preservation profiles (HEARRING group classification) were assessed.
RESULTS RESULTS
All subjects had measurable hearing thresholds at follow-up. No case of complete loss of hearing or minimal hearing preservation was reported at any time point. At activation (N
CONCLUSIONS CONCLUSIONS
This study provides the first longitudinal follow-up on associated hearing profiles to the EVO™ electrode array, which are comparable to the literature. However, other studies on larger populations should be performed.

Identifiants

pubmed: 34884306
pii: jcm10235604
doi: 10.3390/jcm10235604
pmc: PMC8658238
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Acta Otolaryngol Suppl. 2013;(564):3-13
pubmed: 24328756
Otol Neurotol. 2020 Sep;41(8):1060-1065
pubmed: 32569131
Int Arch Otorhinolaryngol. 2016 Oct;20(4):353-358
pubmed: 27746839
HNO. 1993 Jul;41(7):356-9
pubmed: 8376183
Otol Neurotol. 2008 Feb;29(2):168-73
pubmed: 18165793
Arch Otolaryngol Head Neck Surg. 2005 Jun;131(6):488-92
pubmed: 15967880
Acta Otolaryngol. 2005 May;125(5):481-91
pubmed: 16092537
Int J Audiol. 2013 Dec;52(12):838-48
pubmed: 23992489
Otol Neurotol. 2020 Sep;41(8):e993-e1003
pubmed: 32569147
Otol Neurotol. 2015 Aug;36(7):1137-45
pubmed: 25853614
Laryngoscope. 2003 Oct;113(10):1726-30
pubmed: 14520097
Otol Neurotol. 2021 Feb 1;42(2):e145-e152
pubmed: 33026782
Otol Neurotol. 2017 Jun;38(5):678-684
pubmed: 28353622
Eur Arch Otorhinolaryngol. 2020 Mar;277(3):705-713
pubmed: 31802226
Otol Neurotol. 2018 Oct;39(9):e784-e793
pubmed: 30199496
Eur Arch Otorhinolaryngol. 2021 Aug;278(8):2723-2732
pubmed: 32897440
Audiol Neurootol. 2021;26(1):17-26
pubmed: 32721977
Audiol Neurootol. 2006;11 Suppl 1:49-56
pubmed: 17063011
Acta Otolaryngol. 2009 Apr;129(4):372-9
pubmed: 19140036
Otol Neurotol. 2019 Apr;40(4):e373-e380
pubmed: 30870358
Cochlear Implants Int. 2020 Sep;21(5):246-259
pubmed: 32515304
Am J Otol. 1997 Mar;18(2):179-83
pubmed: 9093674
Cochlear Implants Int. 2015 Sep;16(5):277-84
pubmed: 25912363
Otol Neurotol. 2014 Dec;35(10):1765-72
pubmed: 25133472
Acta Otorhinolaryngol Ital. 2015 Dec;35(6):433-41
pubmed: 26900250
Eur Arch Otorhinolaryngol. 2020 Feb;277(2):367-375
pubmed: 31673779
Laryngoscope. 2005 May;115(5):796-802
pubmed: 15867642
Otol Neurotol. 2015 Feb;36(2):354-8
pubmed: 25098590
Audiol Neurootol. 2012;17(5):290-8
pubmed: 22653365
Laryngoscope. 2018 Feb;128(2):482-489
pubmed: 28643327
Laryngoscope. 2018 Aug;128(8):1939-1945
pubmed: 29330858
Audiol Neurootol. 2006;11 Suppl 1:57-62
pubmed: 17063012
Eur Arch Otorhinolaryngol. 2016 Apr;273(4):853-8
pubmed: 25894503
Acta Otolaryngol. 2013 Feb;133(2):116-22
pubmed: 23216055
Otol Neurotol. 2011 Aug;32(6):973-9
pubmed: 21730882
J Craniofac Surg. 2011 Mar;22(2):520-2
pubmed: 21403538
Otol Neurotol. 2016 Oct;37(9):e353-9
pubmed: 27631659
Otol Neurotol. 2020 Jun;41(5):618-624
pubmed: 32080030

Auteurs

Nicolas Guevara (N)

Institut Universitaire de la Face et du Cou (University Institute of the Face and Neck), Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, 06000 Nice, France.

Cécile Parietti-Winkler (C)

Service d'ORL et CCF, CHU Nancy, 54000 Nancy, France.
Laboratoire Développement, Adaptation et Handicap (DevAH-EA 3450), Faculty of Medicine and Faculty of Sciences and Sport, University of Lorraine, Vandoeuvre-lès-Nancy, 54000 Nancy, France.

Benoit Godey (B)

Department of Otolaryngology, Head Neck Surgery, University Hospital Ponchaillou, 35000 Rennes, France.

Valerie Franco-Vidal (V)

Ear, Nose, and Throat Department, Bordeaux University Hospital, 33000 Bordeaux, France.

Dan Gnansia (D)

Research & Technology, Oticon Medical, Technologies and Gene Therapy for Deafness, Hearing Institute, Institut Pasteur/Inserm, 16096 Paris, France.

Marine Ardoint (M)

Research & Technology, Oticon Medical, Technologies and Gene Therapy for Deafness, Hearing Institute, Institut Pasteur/Inserm, 16096 Paris, France.

Michel Hoen (M)

Research & Technology, Oticon Medical, Technologies and Gene Therapy for Deafness, Hearing Institute, Institut Pasteur/Inserm, 16096 Paris, France.

Chadlia Karoui (C)

Research & Technology, Oticon Medical, Technologies and Gene Therapy for Deafness, Hearing Institute, Institut Pasteur/Inserm, 16096 Paris, France.

Eric Truy (E)

Service d'ORL, De Chirurgie Cervico-Faciale et D'audiophonologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Université de Lyon, 69000 Lyon, France.
Centre de Recherches en Neurosciences de Lyon, Équipe IMPACT, INSERM UMRS1028 CNRS UMR5292, 69000 Lyon, France.

Christophe Vincent (C)

Otology and Oto-Neurology Department, Lille University Hospital, 59000 Lille, France.

Isabelle Mosnier (I)

ENT Department, Pitié Salpêtrière Hospital, APHP/Sorbonne Université, 75013 Paris, France.

Yann Nguyen (Y)

ENT Department, Pitié Salpêtrière Hospital, APHP/Sorbonne Université, 75013 Paris, France.
Institut de L'audition Pasteur/Inserm UMR 1120, 75012 Paris, France.

Classifications MeSH